TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Donor Eligibility Criteria:~* Age 18-60~* A history of a positive nasopharyngeal swab for COVID-19 or a history of positive antibody titer test.~* At least 14 days from resolution of COVID-19-associated symptoms including fevers.~* A negative nasopharyngeal swab (or similar test) for COVID-19~* anti-SARS-CoV2 titers \>1:500~* Adequate venous access for apheresis~* Meets donor eligibility criteria in accordance to Hackensack University Medical Center (HUMC) Collection Facility at the John Theurer Cancer Center (JTCC) if collecting at the JTCC, and all regulatory agencies as describes in SOP 800 01.~* Required testing of the donor and product must be performed in accordance to FDA regulations (21 CFR 610.40), and the donation must be found suitable (21 CFR 630.30)~Recipient Eligibility Criteria:~* Patient age \>30 years old, newly diagnosed with a COVID-19 infection with onset of first symptoms \< 96 hours.~* And least one other high-risk feature:~  1. Age \> 65~ 2. BMI 30 or above~ 3. Hypertension, defined as SBP above 140 or DBP above 90, or requiring medication for control.~ 4. Coronary artery disease (history, not ECG changes only)~ 5. Congestive heart failure~ 6. Peripheral vascular disease (includes aortic aneurysm \>= 6 cm)~ 7. Cerebrovascular disease (history of CVA or TIA)~ 8. Dementia~ 9. Chronic pulmonary disease~ 10. Liver disease (such as portal hypertension, chronic hepatitis)~ 11. Diabetes (excludes diet-controlled alone)~ 12. Moderate or severe renal disease defined as having a GFR \< 60 mL/min~ 13. Cancer (exclude if \> 5 year in remission)~ 14. AIDS (not just HIV positive)~Recipient exclusion criteria:~* History of severe transfusion reaction to plasma products~* Need for oxygen supplementation~* Positive test for COVID-19 antibodies~* Chemotherapy-induced neutropenia (ANC \< 0.5 x 103/mcL)~* Immunosuppressive medications except for prednisone (or steroid equivalent) \> 10 mg daily.~* Performance status \< 50 by KPS~* Pneumonia by radiographic evaluation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Convalescent Plasma (Type: EXPERIMENTAL): Fresh or frozen plasma will be infused one time to patients
- Best Supportive Care (Type: ACTIVE_COMPARATOR): Patients will receive best supportive care. Patients randomized to best supportive care may receive plasma should they require hospitalization for progression of COVID-19 disease.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Two Mesh/Fixation Concepts for Laparoscopic Ventral and Incisional Hernia Repair

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed Consent Form (ICF) signed by the patient or his/her legal representative~* primary or secondary ventral hernia less than 20 cm in length and less than 11 cm in width requiring elective surgical repair~* recurrence after former abdominal hernia repair WITH MESH~* recurrence after suture abdominal hernia repair CAN be included~Exclusion Criteria:~* no written informed consent~* patient under 18 years old~* emergency surgery (incarcerated hernia)~* patients with expected life time shorter than one year for example due to generalised malignancy~* BMI exceeding 40.0kg/m²~* contaminated surgical fields~* patients on immunosuppression, steroid therapy, constant pain therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- PH (Type: ACTIVE_COMPARATOR): Intraperitoneal onlay mesh (IPOM) repair with the use of Phisiomesh implant and Securestrap fixation device.
- VS (Type: ACTIVE_COMPARATOR): Intraperitoneal onlay mesh (IPOM) repair with the use of Ventralight ST implant with SorbaFix fixation device.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Preventing Sickle Cell Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pts with HbSS or SB0 thalassemia~* Hypertension from clinic BP readings (defined by NHLBI BP tables)~* Abnormal nocturnal dipping (systolic or diastolic) as defined by \<10% dip or abnormal nocturnal BP load (\>25% of sleep BP readings \>95th percentile as defined by AHA ABPM guidelines)~* Signed Informed Consent~Exclusion Criteria:~* Patient already on BP lowering medication~* Hyperkalemia~* Pregnancy

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Study Arms:
- Standard Blood Pressure Management (Type: ACTIVE_COMPARATOR): Participants initiated on 25mg of losartan daily and randomized to lower in-clinic BP to \<95th percentile
- Experimental Blood Pressure Management (Type: EXPERIMENTAL): Participants initiated on 25mg of losartan daily and randomized to lower in-clinic BP to \<75th percentile

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: CEST- Glucose Enhanced MRI for Metastatic Brain Tumours

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or females~* Between 18 and 65 years of age~* Of all ethnic groups~* BCCA participants with at least one contrast enhancing brain mass with a diameter ≥ 1 cm and consistent with metastatic carcinoma\*~* Able to give consent~* Willingness to participate in the study \* One additional healthy participant will be included in the study to perform a 'test-run' for the complicated MRI and infusion protocol.~Exclusion Criteria:~* Pregnancy~* Diabetes mellitus (self-reported or HbA1C ≥ 6.5%)~* Ferromagnetic implant or foreign metallic bodies (pacemaker, loose metal, etc.)~* Claustrophobia~* History of kidney disease and/or eGFR \< 60~* Abnormal fasting blood glucose (\<70mg/dL or \>125 mg/dL)~* Allergic to corn~* History of adverse reactions to gadolinium based contrast agents~* Poor performance status (Karnofsky PS\<70%)~* Previously received whole brain radiotherapy~* All lesions evident on imaging were previously treated with stereotactic radiosurgery~* The participants weigh more than 300lbs~* The participants had surgery in the last 6 weeks~* The participants have an intrauterine device~* The participants have cosmetic tattoos

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- dynamic glucose enhanced MRI after D-glucose injection (Type: EXPERIMENTAL): IV catheter preparation: Catheter will be placed in one arm. Fasting glucose levels measured with a glucometer using a 1-2 mL sample of blood. Only participants with normal fasting blood glucose levels (70-125 mg/dL) will proceed with the study. First IV catheter will monitor blood glucose every 10 min after bolus injection until it returns to normal. Second IV catheter is placed on the opposite arm for glucose infusion and GBCA (gadobutrol) infusion.~Glucose infusion protocol: Occurs when the participant is in the MRI. Bolus injection of hospital grade 25g of 50% dextrose solution over 1 min is to increase blood glucose concentrations to about 3-4 times the normal level. Blood glucose levels should return to normal levels within 30 to 60 min.~GBCA infusion protocol: Occurs when the participant is in the MRI; approximately 20 min after glucose infusion. Standard intravenous bolus injection of 0.1mM/kg of gadobutrol (Gadovist) at an injection rate of 5 mL/sec.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dose-Dense Induction/Neoadjuvant Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with documented stage III NSCLC (IIIA or IIIB, without malignant pleural/pericardial effusion) are eligible for enrollment if they are considered appropriate for treatment with chemotherapy, radiation, or surgery;~* IIIA: T1-3 N2 M0, T3 N1 M0~* IIIB: T4 N0-2 M0, T 1-4 N3 M0~* Measurable or evaluable disease~* Previously untreated with chemotherapy or radiotherapy for lung cancer;~* No brain metastases;~* No prior XRT~* Performance status 0-2~* ≥18 years of age~* Informed Consent~* Absolute neutrophil count (ANC) ≥ 1.5 x 109/L~* Platelets ≥ 100 x 109/L~* Bilirubin ≤ 1.5 x upper limit of normal for the institution (ULN)~* SGOT and SGPT ≤ 2.5 x ULN for the institution~* Creatinine ≤ 1.6 mg/dL~* Hemoglobin ≥ 8.0 g/dL~* Peripheral neuropathy ≤ grade 1~Exclusion Criteria:~* Known sensitivity to E. coli derived products (e.g. Filgrastim, HUMULIN® insulin, L-asparaginase, HUMATROPE® Growth Hormone, INTRON® A);~* Use of IV systemic antibiotics within 72 hours prior to chemotherapy;~* Known HIV infection~* Lithium or cytokines within 2 weeks prior of entry~* Additional concurrent investigational drugs~* History of myelodysplastic syndrome~* Pregnant, nursing or having unprotected sex~* Not available for follow-up assessment~* Unable to comply with protocol procedures~* Illnesses that may compromise ability to give informed consent.~* Patients with a history of severe hypersensitivity reaction to Taxotere® or other drugs formulated with polysorbate 80.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Induction Chemotherapy (Type: EXPERIMENTAL): Cisplatin 75mg/m2 IV days 1, 15, 29; Docetaxel 75mg/m2 IV days 1, 15, 29; and Pegfilgrastim 6mg SC day 2, 16, 30

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Using Saline for Myofascial Pain Syndromes (USAMPS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients diagnosed with MPS of the trapezius, gluteus medius/minimus, iliocostalis thoracis-lumborum, quadratus Lumborum, or paraspinal muscles in the emergency department.~Exclusion Criteria:~* Patients allergic to lidocaine and/or steroids.~* Pregnant women.~* Prisoners.~* Patients who are cognitively impaired and/or unable to consent for the study.~* Age \< 18.~* Signs of localized infection or skin breakdown at the injection site.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TPI with Normal Saline (Type: EXPERIMENTAL): Trigger point injection (TPI) with 1 mL of normal saline solution. Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
- TPI with Lidocaine & Triamcinolone Acetonide (Type: ACTIVE_COMPARATOR): Trigger point injection (TPI) with 1 mL of conventional drug mix (lidocaine 1%; 10 mL+ triamcinolone acetonide 40 mg/mL). Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Predictive Value of ProCalcitonin for the Detection of Bacteraemia in Patients Presenting to the Emergency Department for Low Risk Chemo-induced Febrile Neutropenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* more than 18 years old~* Patients with solid malignant tumor treated by chemotherapy (neoadjuvant, concomittant, adjuvant or metastatic)~* Febrile neutropenia chemo-induced (fever \> 38°C, neutrophils \< 500 /microliter or nadir \< 500 /microliter)~* Patients non hospitalized at the event (when he presented febrile neutropenia)~* Informed consent signed~Exclusion Criteria:~* Thyroid medullar carcinoma~* Patient not able to understand protocol (mental retardation, psychiatric disorders, .... )

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- the predictive value of ProCalcitonin (Type: OTHER): Patients with solid tumors admitted at the emergency care presenting a febrile neutropenia due to chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~* Subject with a history of moderate to severe atopic dermatitis who participated in the preceding ASN002AD-201 and ASN002AD-101 study~* Subject must be a candidate for prolonged open label ASN002/gusacitinib treatment according to the investigator's judgment.~* Subject has been using an emollient daily for at least 1 week prior to Day 1 and agrees to continue using that same emollient daily throughout the study.~* Men and women participating in the study must use medically acceptable birth control or total abstinence from sexual intercourse~* Subject is willing to participate and is capable of giving informed consent. Note: Consent must be obtained prior to any study-related procedures.~* Subjects must be willing to comply with all study procedures and must be available for the duration of the study.~* Subject has a body mass index (BMI) ≤ 38 kg/m2.~Exclusion Criteria~* Subject is a female who is breastfeeding, pregnant, or who is planning to become pregnant during the study.~* Subject has clinically infected atopic dermatitis.~* A serious uncontrolled condition including hypertension, history of tuberculosis, hepatitis B or C infection, immune deficiency, heart disease, heart conduction disorder, diverticulitis, diabetes, reflux disease requiring protocol pump inhibitor therapy, malabsorption syndrome, or cancer~* Subject has a history of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the study assessments.~* Subject has a history of eczema herpeticum within 12 months, and/or a history of 2 or more episodes of eczema herpeticum in the past.~* Willing to comply with discontinuation of certain treatments for AD, as directed by the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ASN002 40 mg (Type: EXPERIMENTAL): ASN002 40 mg
- ASN002 60 mg (Type: EXPERIMENTAL): ASN002 60 mg
- ASN002 80 mg (Type: EXPERIMENTAL): ASN002 80 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years~* Male patients with histologically or cytologically confirmed adenocarcinoma of the prostate with no evidence of small cell or neuroendocrine features~* Metastatic disease with limited therapeutic options, prior treatment with at least one next-generation hormonal agent (e.g., abiraterone, enzalutamide, apalutamide, darolutamide) and one taxane line of treatment is allowed~* Progressive disease is defined as rising prostate-specific antigen (PSA) levels ≥2ng/mL and/or radiographic progression according to Prostate Cancer Working Group 3 (PCWG3) criteria at screening~* Able and willing to comply with all study requirements for the duration of the study~* Patients must sign an ICF prior to the start of any study-related procedures~Exclusion Criteria:~* Anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy) within 28 days prior to starting study treatment~* Uncontrolled intercurrent illness such as active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled hypertension, or psychiatric illness/social situations that would limit compliance with the study protocol~* Malignancy within the previous 2 years with a ≥30% probability of recurrence within 12 months, with the exception of non-melanoma skin cancer or superficial bladder cancer~* Patients receiving strong inhibitors or inducers of cytochrome P450 (CYP) 3A4~* Chronic use of systemic steroid therapy (\>1 month of \>10 mg prednisone per day or equivalent, except replacement therapy)~* Patients for whom biopsies cannot be taken or are not willing to undergo biopsies~* Positive hepatitis B virus (HBV) surface antigen, hepatitis B core antibody, positive hepatitis C virus (HCV) antibody, and/or HIV-antigen-antibody test at screening

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IMU-935 - low dose, administered twice daily (Type: EXPERIMENTAL): main treatment phase of 3 cycles of 28 days; followed by extended treatment cycles for patients that show clinical benefit from treatment
- IMU-935 - medium dose, administered twice daily (Type: EXPERIMENTAL): main treatment phase of 3 cycles of 28 days; followed by extended treatment cycles for patients that show clinical benefit from treatment
- IMU-935 - high dose, administered twice daily (Type: EXPERIMENTAL): main treatment phase of 3 cycles of 28 days; followed by extended treatment cycles for patients that show clinical benefit from treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Temozolomide in Patients Affected by Relapsed Sensitive or Refractory Small Cell Lung Cancer With MGMT Methylation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed SCLC with MGMT methylation.~* Patient previously treated by one or two chemotherapy lines.~* Age ≤ 75 and Eastern Cooperative Oncology Group (ECOG) Performance Status ≤2.~* Patients must have measurable disease, defined as at least one lesion than can be accurately measured in at least one dimension (longest diameter to be recorded) as \> 20mm with conventional techniques or as \>10mm with spiral CT scan.~* Patient with controlled brain metastases are eligible.~* Patient previously treated with chest and/or brain RT are eligible.~* Life expectancy \>3 months.~* Patient must have normal organ and marrow function as defined below: leukocytes \>3,000/μL, absolute neutrophil count \>1,000/μL, platelets\>100,000/μL, total bilirubin within normal institutional limits, AST(SGOT)/ALT(SGPT) \<2.5 X institutional upper limit of normal, creatinine within normal institutional limits~* Female participants of child bearing potential and male participants whose partner is of child bearing potential must be willing to ensure that they or their partner use effective contraception during the study and for 3 months thereafter.~* Ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~* Histologically or cytologically confirmed SCLC without MGMT methylation.~* Patients who have received three or more previous chemotherapy lines for small cell lung cancer or radiotherapy on target lesions.~* Symptomatic uncontrolled CNS metastasis.~* Participation in another clinical trial with any investigational agents within 30 days prior to study screening.~* Presence of infection.~* History or evidence of malabsorption syndrome or disease that may significantly affect gastrointestinal function.~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide or other agents used in the study.~* Presence of medical problems of sufficient severity to prevent full compliance with the study.~* Other known malignant neoplastic diseases in the patient's medical history with a disease-free interval of less than 5 years (except for previously treated basal cell carcinoma and in situ carcinoma of the uterine cervix).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Temozolomide (Type: EXPERIMENTAL): oral Temozolomide 200 mg/m2/die for 5 consecutive days, every 28 days.Treatment will be continued until tumor progression, intolerable toxicity or patient refusal

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues